2010
DOI: 10.1007/s00296-010-1685-x
|View full text |Cite
|
Sign up to set email alerts
|

Multi-center evaluation of autoantibodies to the major ribosomal P C22 epitope

Abstract: Anti-ribosomal P (Rib-P) autoantibodies have been demonstrated to be a specific diagnostic marker for systemic lupus erythematosus (SLE). The aim of this study was to evaluate the prevalence of anti-Rib-P (C22) antibodies in patients with SLE drawn from international, multi-center clinics. Sera collected from patients with SLE (n = 333) and various controls (n = 397) in four centers were tested for anti-C22 autoantibodies by ELISA (Dr. Fooke Laboratorien). SLE activity index 2000 (SLEDAI-2K) was assessed for e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
15
0
1

Year Published

2013
2013
2021
2021

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 19 publications
(17 citation statements)
references
References 37 publications
1
15
0
1
Order By: Relevance
“…Moreover, our data gave evidence for an association of anti-Rib-P with disease activity. Noteworthy, a recent multicenter evaluation reported a relationship between anti-Rib-P (C22) and SLEDAI scores only for a subgroup of participants and concluded that this serological parameter is likely not appropriate for measuring global disease activity (14). Considering that there are other reports substantiating or refuting this association (10)(11)(12)(13)15,36), further prospective large-scale studies may clarify this issue.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Moreover, our data gave evidence for an association of anti-Rib-P with disease activity. Noteworthy, a recent multicenter evaluation reported a relationship between anti-Rib-P (C22) and SLEDAI scores only for a subgroup of participants and concluded that this serological parameter is likely not appropriate for measuring global disease activity (14). Considering that there are other reports substantiating or refuting this association (10)(11)(12)(13)15,36), further prospective large-scale studies may clarify this issue.…”
Section: Discussionmentioning
confidence: 99%
“…For Asian patients, higher prevalences have been reported compared to Afro-Americans and Caucasians (5)(6)(7)(8)(9)(10). Reports about clinical associations of anti-Rib-P antibodies are in part controversial, including disease activity (10)(11)(12)(13)(14)(15), neuropsychiatric symptoms (6,(16)(17)(18)(19)(20)(21)(22)(23), lupus nephritis (12,(24)(25)(26), hepatic involvement (26)(27)(28), skin manifestations (11), juvenile SLE (12,29), and others (1,30).…”
Section: Introductionmentioning
confidence: 99%
“…The receiving operator curve (ROC) was also applied to evaluate the different methods available [20,[26][27][28]. The antigens used range from short synthetic peptides or recombinant proteins to macromolecular complexes.…”
Section: Methods Of Evaluations For Antiribosomal P Antibody Levelsmentioning
confidence: 99%
“…The Rib-P are largely localized to the cytoplasm and are components of the 60S ribosomal subunit [93]. Over the years, anti-Rib-P antibodies have been the subject of extensive study and have been shown to be a highly specific biomarker for the diagnosis of SLE [97][98][99]. They are associated with LN, autoimmune hepatitis and, although controversial, with neuropsychiatric SLE (NPSLE) subset [100,101].…”
Section: Ribosomal Pmentioning
confidence: 99%
“…A significant challenge in interpreting the published literature is the variability of diagnostic platforms used to detect anti-Rib-P and the antigens included in the assays. Evidence indicates that the major epitope is localized to the C-terminal 22 amino acids [98,102], and some diagnostic assays use this analyte in their assays but other assays use various combinations of the other Rib-P's [103,104]. This likely accounts for the marked discrepancies in frequencies (10-47%) and association with clinical and demographic features reported in SLE cohorts.…”
Section: Ribosomal Pmentioning
confidence: 99%